Tirzepatide 40mg vs Semaglutide vs CagriSema: Complete Receptor & Efficacy Comparison
How GIP co-agonism in Tirzepatide buffers gastrointestinal side effects while CagriSema pairs Amylin with GLP-1 for deep hypothalamic satiety signaling.
GEO: EU Clinics, Spain & Italy, France & Monaco, Cyprus
Scientific Review: Dr. Lukas V. Meyer, Ph.D. (Head of Analytical Chemistry, Synedica Basel R&D)
- Semaglutide (8mg): Selective GLP-1 agonist — ideal for initiation and long-term glycemic maintenance.
- Tirzepatide (40mg): Dual GIP/GLP-1 agonist — superior insulin sensitivity and reduced nausea via GIP central buffering.
- CagriSema (4mg+4mg): Dual GLP-1 + Amylin — targets two independent satiety centers in the brainstem and hypothalamus.
- CagriReta: Quadruple pathway synergy for refractory metabolic resistance.
1. Why GIP Makes Tirzepatide Smoother Than Monotherapy GLP-1
While GLP-1 strongly suppresses appetite, high doses can trigger nausea in sensitive individuals. Glucose-dependent insulinotropic polypeptide (GIP) acts on GABAergic neurons in the area postrema, naturally attenuating emetic signaling while enhancing white adipose tissue lipid buffering.
2. Head-to-Head Formulation Matrix
Compare the four flagship metabolic pen kits produced by Synedica Laboratories:
| Formulation | Active Pathways | Total Kit Potency | Avg. Clinical Weight Loss | Best Suited For |
|---|---|---|---|---|
| Semaglutide | GLP-1 (100%) | 8 mg (2x 4mg pens) | ~14.9% | First-time protocol & maintenance |
| Tirzepatide | GIP (100%) + GLP-1 (90%) | 40 mg (4x 10mg) | ~20.9% | Smooth GI tolerance & insulin resistance |
| CagriSema | GLP-1 (100%) + Amylin (100%) | 4mg + 4mg Dual Pens | ~22.7% | Stubborn appetite & emotional cravings |
| Retatrutide | GLP-1 + GIP + Glucagon | 40 mg (4x 10mg) | ~24.2% | Maximum visceral fat & metabolic rate |